© 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights. All rights reserved.
The Pharmacist's Role in Improving the Clinical Outcomes of Patients with Schizophrenia
This activity is supported by an educational grant from Otsuka America Pharmaceutical, Inc.
The Pharmacist’s Role in Improving the Clinical Outcomes of Patients with Schizophrenia
Faculty
Tammie Lee Demler, BS, PharmD, MBA, BCPP
Director of Pharmacy Services and Residency Training
New York State Office of Mental Health
The Buffalo Psychiatric Center
Clinical Associate Professor,
University of Buffalo, School of Pharmacy and Pharmaceutical Sciences
Clinical Assistant Professor,
D’Youville College of Pharmacy
Clinical Assistant Professor,
University of Florida, School of Pharmacy, Gainesville, Florida
Educational Objectives:
After completing this continuing education program, the participant will be able to:
- Examine the epidemiology, pathophysiology, and clinical progression of schizophrenia
- Describe common adverse events that often accompany schizophrenia therapies, and strategies for monitoring and mitigating these effects
- Identify issues affecting the successful management of schizophrenia
- Examine the pharmacist’s role for improving clinical outcomes in schizophrenia
Target audience:
Pharmacists
Type of activity:
Knowledge
Release date:
March 6, 2015
Expiration date:
March 6, 2017
Estimated time to complete activity:
2.0 hours
Pharmacy Times Office of Continuing Professional Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This activity is approved for 2.0 contact hours (0.20 CEUs) under the ACPE universal activity number 0290-0000-15-017-H01-P. The activity is available for CE credit through March 6, 2017.